 BEVERLY HILLS, Calif., June 8, 2021 PRNewswire -- GT Biopharma, Inc. GT Biopharma or the Company NASDAQ: GTBP, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary natural killer NK cell engager TriKETM protein biologic technology platform, today announced that it is set to be added to the Russell 2000 Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021. 